Ethambutol-d4 Dihydrochloride (CAS 1129526-19-7)

Ethambutol-d4 dihydrochloride is a deuterium-labeled derivative of ethambutol, a frontline antibiotic used in the treatment of tuberculosis. Its mechanism of action primarily involves inhibition of arabinosyltransferases, enzymes responsible for the synthesis of arabinogalactan, an essential component of the mycobacterial cell wall. By disrupting cell wall biosynthesis, ethambutol-d4 impairs the integrity and permeability of the bacterial membrane, ultimately leading to bacterial growth inhibition. Research applications of ethambutol-d4 dihydrochloride extend beyond its antimicrobial properties, particularly in studies investigating drug metabolism, pharmacokinetics, and pharmacodynamics. As a deuterium-labeled compound, ethambutol-d4 serves as a valuable tool in drug metabolism studies, enabling researchers to trace the fate of ethambutol in biological systems using mass spectrometry-based techniques. Moreover, its use in stable isotope labeling studies facilitates accurate quantification of drug concentrations and metabolic pathways, contributing to a deeper understanding of drug-drug interactions, bioavailability, and pharmacokinetic profiles. Ethambutol-d4 dihydrochloride thus represents a crucial research tool for elucidating the pharmacological properties and mechanisms of action of ethambutol and other antimicrobial agents, aiding in the development of more effective strategies against tuberculosis and related infectious diseases.